Scott & White Healthcare study aimed at T-cell lymphoma

Jul 15, 2010

Scott & White's Cancer Research Institute (CRI) is conducting a clinical trial that targets malignant T-cell lymphoma, a type of blood cancer.

Lymphoma, which affects the white blood cells that normally protect against illness, is categorized either as B-cell or T-cell. About 85% of lymphomas are of B-cell origin, and 15% of T-cell origin. T-cell lymphomas are primarily chronic, but they do not respond well to chemotherapy.

Therefore, says Arthur E. Frankel, M.D., director of the Research Institute and director of Scott & White's Division of hematology/oncology, the need exists to find new agents that can selectively target and kill the malignant T-cells. The research agent under study at Scott & White contains diphtheria targeting malignant T-cells.

"This new targeted protein agent is designed to eliminate tumor cells resistant to chemotherapy," said Dr. Frankel. "The short course of treatment may improve quality of life if successful."

To date, 10 people have enrolled in the clinical trial. Scott & White's CRI will enroll up to 40 subjects to participate in this clinical trial to determine the safest doses for treatment of T-cell . Eligible subjects for the study must have failed previous treatment options.

T-cell malignant diseases include MF/Sezary Syndrome, T-cell LGL, PTCL, T-cell CLL, T-cell NHL, angioimmunoblastic T-cell lymphoma, T-cell anaplastic large cell lymphoma, nasal extranodal T-cell lymphoma, enteropathy-type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, and hepatosplenic T-cell lymphoma.

Explore further: Too many Americans neglect backs in skin cancer prevention

Related Stories

News from Cancer: Risk factors for deadly form of lymphoma

Jul 07, 2008

A new study indicates that the incidence of mantle cell lymphoma, an aggressive type of non-Hodgkin's lymphoma, is on the rise, most frequently striking men, Caucasians and older individuals. The study, published in the August ...

Recommended for you

Women's use of talc powder may be tied to ovarian cancer

1 hour ago

Deane Berg's doctor called her in the day after Christmas 2006 to give her the crushing news. She'd had her ovaries removed, the pathology results were back, and the information could not have been much worse. Berg had stage ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.